SecBot

SecBot
Nasdaq· CIK 0002114044

COAG

Hemab Therapeutics Holdings, Inc.
$30.36 ▼ -2.25%
Prev close $31.06
Market cap$1.4B
ConsensusStrong Buy
12-mo target$61.20 (+101.7%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)9 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on COAG right now — valuation, ownership and activity at a glance.
Market Cap
$1.4B
Cap Size
Small Cap
Analyst Consensus
Strong Buy (91%)
Inst. Holders
36 funds
Inst. Value
$808.0M
Inst. Activity
9 buys / 0 sells
Insider Activity
$55.5M buy / $0.00 sell
Insider Net $
$55.5M
SEC Reports
12
Press Releases
1
Price chart 30d -32.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 other
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
Keli Walbert brings two decades of commercial leadership and proven track record of successful launc
Sep 24, 2026 Insider
Walbert Keli was granted 36,000 shares
Director
Aug 11, 2026 SEC
Hemab Therapeutics reported Q2 2026 net loss of $24.2M ($0.80/share), wider than the $12.2M loss in Q2 2025 but in line
8-K — Impact 7/10
Jun 30, 2026 Inst.
RA CAPITAL MANAGEMENT, L.P. — NEW
7,808,627 shares ($286.8M)
Jun 30, 2026 Inst.
FMR LLC — NEW
3,697,837 shares ($135.8M)
Jun 17, 2026 SEC
RA Capital Management, L.P., a 10% owner, purchased $153K of COAG shares on the open market at $24.89. The buy is trivia
INSIDER-BUY — Impact 2/10
Jun 16, 2026 Insider
RA CAPITAL MANAGEMENT, L.P. bought 61,523 shares
10%+ Owner @ $24.98 ($1.5M)
Jun 15, 2026 Insider
RA CAPITAL MANAGEMENT, L.P. bought 6,146 shares
10%+ Owner @ $24.89 ($153.0K)
Analyst ratings buy % +2.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Strong Buy 91% rate it Buy or better · 11 analysts
Strong Buy 4 36% Buy 6 55% Hold 1 9% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Aug 12, 2026WedbushMAINTAINOutperform 57%
Aug 11, 2026HC Wainwright & Co.MAINTAINBuy 43%
Jul 13, 2026JefferiesMAINTAINBuy 53%
Jul 13, 2026WedbushMAINTAINOutperform 57%
Jul 13, 2026HC Wainwright & Co.MAINTAINBuy 43%
Jun 26, 2026HC Wainwright & Co.REITERATEBuy 43%
Jun 17, 2026HC Wainwright & Co.INITIATEBuy 43%
May 26, 2026WedbushINITIATEOutperform 57%
May 26, 2026JefferiesINITIATEBuy 53%
May 26, 2026Evercore ISI GroupINITIATEOutperform 59%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 20264610091%
Aug 1, 20264610091%
Jul 1, 20264610091%
Jun 1, 20263510089%
Price targets
Where 5 covering analysts think COAG trades over the next 12 months.
$61.20 +101.7% upside Strong Buy
Current$30.34 Low$58.00 Median$60.00 High$65.00 5 analysts
$58.00$65.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 1 bullish, 0 bearish, 1 mixed, 10 neutral · avg impact 3.3/10.Plus 1 press releases.
BULLISH8-K7/10
Hemab Therapeutics reported Q2 2026 net loss of $24.2M ($0.80/share), wider than the $12.2M loss in
Aug 11, 2026
NEUTRALINSIDER-BUY2/10
RA Capital Management, L.P., a 10% owner, purchased $153K of COAG shares on the open market at $24.8
Jun 17, 2026
NEUTRALPRESS-RELEASE5/10
Hemab Therapeutics reported a Q1 2026 net loss of $22.7M ($23.98/share), widening from a $15.3M loss
May 21, 2026
NEUTRAL8-K4/10
Hemab Therapeutics completed its IPO of 19,262,500 shares at $18.00/share, raising $346.7M in gross
May 4, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 24, 2026
other
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board Keli Walbert brings two decades o
Sep 17, 2026
fda
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecolog
Sep 15, 2026
short_interest_report
Short Interest: COAG up 25% to 2.6M shares
Settlement 2026-09-15 | Days to cover: 7.54 | ≈5.65% of shares outstanding (est.)
Aug 27, 2026
ftd
FTD: COAG — 25,800 shares ($1.3M) failed to deliver
Settlement: 20260827, Price: $49.19, FTD Value: $1,269,102, HEMAB THERAPEUTICS HLDGS INC C
Aug 11, 2026
earnings
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemos
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-0.51$-0.55–$-0.41—-4.8%0↑ 2↓$0.0B4
Next Q$-0.57$-0.62–$-0.50—+1.9%2↑ 1↓$0.0B4
Current FY$-3.10$-3.23–$-2.77—-1.2%1↑ 2↓$0.0B4
Next FY$-2.54$-2.81–$-2.3018.1%-3.7%1↑ 2↓$0.0B4
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-0.510—
7d ago$-0.487-0.023
30d ago$-0.487-0.023
60d ago$-0.460-0.050
90d ago$0.000-0.510
Institutional ownership
Which big funds own COAG (from quarterly 13F filings) and who is adding or trimming.
36 institutional holders with $808.0M total value (22,742,478 shares) as of 2026-Q2. Top holders: RA, FMR, Capital. Net buying activity: 9 institutions added/increased vs 0 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
RA CAPITAL MANAGEMENT, L.P.7,808,627$286.8M35.5%NEW
FMR LLC3,697,837$135.8M16.8%NEW
Capital International Investors3,603,876$132.4M16.4%NEW
Avoro Capital Advisors LLC1,925,150$70.7M8.8%NEW
JPMORGAN CHASE & CO1,152,420$42.3M5.2%NEW
VANGUARD CAPITAL MANAGEMENT LLC780,758$28.7M3.5%NEW
DRIEHAUS CAPITAL MANAGEMENT LLC715,791$26.3M3.3%NEW
CITADEL ADVISORS LLC523,450$19.2M2.4%NEW
BlackRock, Inc.283,833$10.4M1.3%NEW
ExodusPoint Capital Management, LP218,287$8.0M1.0%—
Recent position changes
FundActionPrevCurrentChangeValue
RA CAPITAL MANAGEMENT, L.P.NEW—7,808,627—$286.8M
FMR LLCNEW—3,697,837—$135.8M
Capital International InvestorsNEW—3,603,876—$132.4M
Avoro Capital Advisors LLCNEW—1,925,150—$70.7M
JPMORGAN CHASE & CONEW—1,152,420—$42.3M
VANGUARD CAPITAL MANAGEMENT LLCNEW—780,758—$28.7M
DRIEHAUS CAPITAL MANAGEMENT LLCNEW—715,791—$26.3M
CITADEL ADVISORS LLCNEW—523,450—$19.2M
BlackRock, Inc.NEW—283,833—$10.4M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
5 insiders, 35 transactions. Net $55.5M — $55.5M bought, $0.00 sold.
DateInsiderTitleTypeSharesPriceValue
Sep 24, 2026Walbert KeliDirectorAWARD36,000——
Jun 16, 2026RA CAPITAL MANAGEMENT, L.P.10%+ OwnerBUY61,523$24.98$1.5M
Jun 15, 2026RA CAPITAL MANAGEMENT, L.P.10%+ OwnerBUY6,146$24.89$153.0K
May 20, 2026RA CAPITAL MANAGEMENT, L.P.10%+ OwnerBUY996$24.94$24.8K
May 19, 2026RA CAPITAL MANAGEMENT, L.P.10%+ OwnerBUY3,802$24.97$94.9K
May 12, 2026RA CAPITAL MANAGEMENT, L.P.10%+ OwnerBUY6,387$24.90$159.0K
May 11, 2026RA CAPITAL MANAGEMENT, L.P.10%+ OwnerBUY25,720$25.00$643.0K
May 11, 2026RA CAPITAL MANAGEMENT, L.P.10%+ OwnerBUY14,149$24.47$346.2K
May 8, 2026RA CAPITAL MANAGEMENT, L.P.10%+ OwnerBUY1,483$24.98$37.0K
May 7, 2026RA CAPITAL MANAGEMENT, L.P.10%+ OwnerBUY1,985$24.95$49.5K
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for COAG.
Shares short
2,641,038
Settlement Sep 15, 2026
Change vs prior
+25.3%
Semi-monthly cycle
Days to cover
7.5
At avg daily volume
Of shares outstanding
≈5.7%
Estimate — not % of float
All COAG filing & press-release reports (13)